RxDoctor Payments Data

Rena Ferguson, MD

Psychiatry · Port Jefferson, NYNPI 1013082452

Payments from drug & device makers

$19,508in general payments, 2019–2025

Across 866 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • Alkermes, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • plus $9K from 29 others

What the payments were for

  • Food & beverage$19,36399%
  • Education$1451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,508 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$789,963
Medicare patients
276
Services billed
4,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine13$117,087
RexultiBrexpiprazole26$86,686
AustedoDeutetrabenazine16$49,687
CaplytaLumateperone Tosylate20$40,668
AuvelityDextromethorphan Hbr/Bupropion18$36,605
SpravatoEsketamine Hcl18$23,696
BelsomraSuvorexant24$9,032
FetzimaLevomilnacipran Hcl17$8,693
Lurasidone Hcl12$7,814
QuviviqDaridorexant Hcl13$6,093
Lisdexamfetamine Dimesylate11$2,859
Quetiapine Fumarate102$1,938
Bupropion XlBupropion Hcl69$1,864
Mirtazapine35$1,616
Clozapine28$1,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$1,992$166,77429 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,595$86,68626 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,742$40,66820 claims
Axsome Therapeutics, Inc.Auvelity$380$36,60518 claims
Johnson & JohnsonSpravato$1,574$23,69618 claims
MerckBelsomra$230$9,03224 claims
AbbVieFetzima$1,039$8,69317 claims
Idorsia Pharmaceuticals US IncQuviviq$139$6,09313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Port Jefferson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →